Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Podophyllotoxin (topo II)
Teniposide
Vumon · VM-26
A highly protein-bound podophyllotoxin whose renal relevance is pharmacokinetic — low renal clearance and exposure, not direct nephron injury.
Mild1992 podophyllotoxin · approved 1992
Refractory childhood acute lymphoblastic leukemia (combination therapy)Selected CNS tumors and other malignancies (regimen-dependent)
Signature kidney injury
Electrolyte Wasting
Minimal direct nephrotoxicity. Teniposide is highly protein-bound with low renal clearance (only ~10-25% of a dose is recovered in urine versus a larger fraction for etoposide), so the kidney is a minor elimination route and direct renal injury is not a characteristic toxicity. Renal relevance is pharmacokinetic/exposure-related and not quantified as a discrete nephrotoxicity rate.
Source: Clark, Semin Oncol 1992
Mechanism of kidney injury
No well-defined direct tubular toxin mechanism. Because teniposide is extensively protein-bound and undergoes limited renal excretion, renal dysfunction has comparatively modest effects on its clearance relative to etoposide; the practical concern is altered exposure (and free-fraction shifts with hypoalbuminemia) rather than structural nephron injury. Electrolyte and prerenal changes, when seen, reflect supportive-care context rather than direct toxicity.
Clinical presentation
Direct renal presentation is uncommon. In practice, any renal-related findings are typically electrolyte disturbances or prerenal physiology in the setting of intensive leukemia therapy. Hypersensitivity/infusion reactions and myelosuppression dominate the clinical toxicity profile.
Onset
No characteristic renal onset; pharmacokinetic exposure effects are immediate but clinically modest.
Reversibility
Reversible
Anticancer mechanism
Teniposide (VM-26) is a semisynthetic podophyllotoxin derivative and topoisomerase II poison: it stabilizes the enzyme-DNA cleavable complex, producing double-strand DNA breaks and arrest in late S/early G2 phase. More potent and more highly protein-bound than its analog etoposide, it is used chiefly in childhood acute lymphoblastic leukemia (often refractory disease) and has activity in selected CNS and other tumors.
Management
No drug-specific renal antidote is needed. Provide supportive care, correct electrolytes and volume, and individualize dosing for organ dysfunction. Manage the dominant toxicities (hypersensitivity, myelosuppression) per protocol.
Risk factors
- Hypoalbuminemia (raises free drug fraction)
- Severe renal or hepatic impairment (altered clearance)
- Concomitant nephrotoxins or prerenal insults in intensive regimens
Prevention
- Account for protein binding and hypoalbuminemia when dosing
- Maintain hydration; avoid stacking nephrotoxins
- Monitor electrolytes during intensive leukemia therapy
Note · Contrast with etoposide: teniposide's higher protein binding, longer terminal half-life, and lower renal/plasma clearance mean renal dysfunction perturbs its handling less — the teaching point is PK/clearance, not nephrotoxicity.
Clinical depth
Renal dose adjustment
No standardized renal dose-reduction schema is well established given low renal clearance; use caution and consider individualized reduction in severe renal or hepatic impairment and with marked hypoalbuminemia. Follow local protocol.
Dialyzability & ESKD dosing
Not meaningfully dialyzable: extensive (>99%) plasma protein binding and a relatively small free fraction make removal by hemodialysis negligible. Do not rely on dialysis for clearance.
Differential diagnosis
In a leukemia patient with rising creatinine, look first to tumor lysis syndrome, sepsis/prerenal states, nephrotoxic co-medications, and contrast — teniposide itself is rarely the direct cause. Its renal footprint is pharmacokinetic.
Monitoring
- CBC (myelosuppression is dose-limiting)
- Electrolytes during intensive therapy
- Renal and hepatic function for dosing context
- Serum albumin (affects free drug fraction)
- Infusion-reaction monitoring
Key trials & series
- Clark 1992 — clinical pharmacology of podophyllotoxin derivatives: teniposide has greater protein binding, longer half-life, and reduced plasma and renal clearance vs etoposide
- Clark & Slevin 1987 — comparative clinical pharmacokinetics of etoposide and teniposide (only ~5-20% of teniposide excreted/recovered, vs more for etoposide)
Clinical pearls
- Teniposide is the more protein-bound, more slowly cleared cousin of etoposide — renal dysfunction affects it less.
- Only about 10-25% of a teniposide dose appears in urine, so the kidney is a minor exit route.
- Very high protein binding makes dialysis ineffective for removal.
- Hypoalbuminemia raises the free fraction — a more relevant dosing concern than direct nephrotoxicity.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Electrolyte WastingPrerenal / Hemodynamic AKI
Evidence
3 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkClinical pharmacology and schedule dependency of the podophyllotoxin derivatives.Clark PI · Semin Oncol 1992 · PMID 1411635States teniposide has greater protein-binding affinity, longer half-life, and reduced plasma and renal clearance than etoposide — the basis for its PK-driven renal relevance.PMIDThe clinical pharmacology of etoposide and teniposide.Clark PI et al. · Clin Pharmacokinet 1987 · PMID 3297462Comparative PK review documenting that only ~5-20% of teniposide is excreted/recovered (vs more for etoposide), confirming minimal renal elimination.PMIDConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology reference framing which conventional cytotoxics carry meaningful kidney risk, contextualizing teniposide's low direct nephrotoxic profile.